CL: UBS Maintains Buy Rating, Raises Price Target May 2026

UBS maintained its Buy rating on Colgate-Palmolive (CL) on May 4, 2026, signaling continued confidence in the consumer staples giant. The analyst firm raised its price target to $100 from $98, reflecting modest upside potential from current levels. This analyst rating maintained stance comes as CL trades near $85.37, down slightly from recent highs. The company’s strong brand portfolio and consistent dividend payments continue to attract institutional investors seeking defensive exposure in uncertain markets.

UBS Maintains Buy Rating with Higher Price Target

Analyst Rating Maintained

UBS kept its Buy rating intact while raising the price target to $100 from $98, demonstrating sustained bullish sentiment on Colgate-Palmolive. This analyst rating maintained action reflects confidence in the company’s long-term fundamentals despite near-term market volatility. The $2 increase in the target price suggests UBS sees approximately 17% upside potential from current trading levels around $85.37.

Price Target Implications

The new $100 price target represents meaningful upside for investors holding CL shares. At the time of the analyst rating maintained announcement, the stock was trading at $85.96, giving investors a clear price objective. This target aligns with the company’s historical trading range and reflects UBS’s belief in steady earnings growth and dividend sustainability over the next 12 months.

Colgate-Palmolive Financial Position and Market Standing

Market Capitalization and Stock Performance

Colgate-Palmolive commands a market capitalization of approximately $68.5 billion, making it one of the largest consumer staples companies globally. The stock currently trades at $85.37, down 2.17% on the day but up 8.04% year-to-date. The company’s 52-week range spans from $74.55 to $99.33, showing meaningful volatility despite its defensive sector classification. UBS raised its price target to $100 from $98, providing a concrete upside target for investors.

Dividend Yield and Income Appeal

CL offers a dividend yield of approximately 2.45%, with an annual dividend per share of $2.09. The payout ratio stands at 87.88%, indicating the company returns most earnings to shareholders. This income-focused profile attracts retirees and conservative investors seeking stable cash flows from established consumer brands like Colgate, Palmolive, and Hill’s Pet Nutrition.

Analyst Consensus and Meyka AI Grade

Broad Analyst Support

Colgate-Palmolive enjoys strong analyst backing with 17 Buy ratings and no Sell or Hold recommendations in the current consensus. This unanimous bullish stance reflects industry-wide confidence in the company’s competitive moat and pricing power. The analyst rating maintained by UBS aligns with this broader market view, suggesting the stock remains attractive despite recent price weakness.

Meyka AI Grade Assessment

Meyka AI rates CL with a grade of B+, reflecting solid fundamental strength and market positioning. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B+ rating suggests the stock offers reasonable value for long-term investors, though it’s not considered a top-tier opportunity. These grades are not guaranteed and we are not financial advisors.

Key Metrics and Valuation Considerations

Valuation Multiples

Colgate-Palmolive trades at a P/E ratio of 32.77x, which is elevated compared to historical averages but reflects the defensive nature of consumer staples. The price-to-sales ratio stands at 3.29x, indicating investors pay a premium for the company’s brand strength and market position. Free cash flow yield of 5.51% demonstrates solid cash generation relative to market value, supporting the dividend.

Earnings and Cash Flow Strength

The company generates $2.63 in earnings per share and $4.70 in free cash flow per share annually. Operating margins of 21.21% showcase pricing power and operational efficiency across global markets. With earnings announcement scheduled for July 31, 2026, investors will gain fresh insight into execution against analyst expectations and the sustainability of the analyst rating maintained by UBS.

Final Thoughts

UBS raised Colgate-Palmolive’s price target to $100, maintaining its Buy rating based on the company’s strong brands, consistent cash flow, and pricing power. With 17 Buy ratings and no Sell recommendations, analyst consensus is solidly bullish. Meyka AI’s B+ grade supports this outlook. The stock’s current weakness near $85 offers an attractive entry point for income-focused investors seeking exposure to a resilient global consumer staples leader.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.